Polymorphisms associated with adalimumab and infliximab response in moderate to-severe plaque psoriasis

Simple item page
dc.centroUniversidad San Pablo-CEU
dc.contributor.authorPrieto Pérez, Rocío
dc.contributor.authorLlamas Velasco, Mar
dc.contributor.authorMuñoz Aceituno, Ester
dc.contributor.authorReolid, Alejandra
dc.contributor.authorSaiz Rodríguez, Miriam
dc.contributor.authorBelmonte, Carmen
dc.contributor.authorRomán, Manuel
dc.contributor.authorOchoa Mazarro, Dolores
dc.contributor.authorTalegón, María
dc.contributor.authorCabaleiro, Teresa
dc.contributor.authorDaudén, Esteban
dc.contributor.authorAbad-Santos, Francisco
dc.contributor.authorOvejero Benito, María del Carmen
dc.date.accessioned2024-05-10T16:52:28Z
dc.date.available2024-05-10T16:52:28Z
dc.date.issued2017-12-01
dc.descriptionVersión en abierto siguiendo la política de la revistaes_ES
dc.description.abstractAims-. This study evaluated the influence of pharmacogenetics in psoriatic patients treated with adalimumab and/or infliximab. Materials and methods-. Prospective observational study evaluating the association of 124 polymorphisms with the response to adalimumab or infliximab (PASI75) in patients with moderate-to-severe plaque psoriasis at 3 months (N=95) and 6 months of treatment (N=90). Significant SNPs for univariate analysis were subjected to multivariate analysis. Results/Conclusions-. Five SNPs were associated with PASI75 at 3 months: rs6661932 (IVL), rs2546890 (IL12B), rs2145623 (NFKBIA), rs9304742 (ZNF816A) and rs645544 (SLC9A8). Furthermore, rs1061624 (TNFR1B) was associated with PASI75 at 6 months. Nevertheless, these biomarkers should be validated in large-scale studies before implementation in clinical practice.es_ES
dc.formatapplication/pdf
dc.identifier.citationOvejero-Benito MC, Prieto-Pérez R, Llamas-Velasco M, Muñoz-Aceituno E, Reolid A, Saiz-Rodríguez M, Belmonte C, Román M, Ochoa D, Talegón M, Cabaleiro T, Daudén E, Abad-Santos F. Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis. Pharmacogenomics. 2018 Jan;19(1):7-16. doi: 10.2217/pgs-2017-0143es_ES
dc.identifier.doi10.2217/pgs-2017-0143
dc.identifier.issn1744-8042
dc.identifier.urihttp://hdl.handle.net/10637/15772
dc.language.isoenes_ES
dc.publisherFuture Medicinees_ES
dc.relation.ispartofPharmacogenomics
dc.rightsopen access
dc.rights.cchttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subjectPsoriatic patientses_ES
dc.subjectPharmacogeneticses_ES
dc.titlePolymorphisms associated with adalimumab and infliximab response in moderate to-severe plaque psoriasises_ES
dc.typeArtículoes_ES
dspace.entity.typePublicationes
relation.isAuthorOfPublication95639da1-55e7-4f9c-9f67-28676cc5aca2
relation.isAuthorOfPublication.latestForDiscovery95639da1-55e7-4f9c-9f67-28676cc5aca2

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Polymorphism_Ovejero_et_al_PHAR_2018.pdf
Size:
1.18 MB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Facultad de Farmacia
x

The user has the obligation to use the services and content provided by the University, in particular, printed and electronic resources, in accordance with current legislation and the principles of good faith and generally accepted uses, without contravening with its performance the public order, especially, in the case in which, for the adequate performance of its activity, it needs to reproduce, distribute, communicate and/or make available, fragments of printed works or capable of being in analog or digital format, either on paper or electronic support. Law 23/2006, of July 7, which modifies the revised text of the Intellectual Property Law, approved by Royal Legislative Decree 1/1996, of April 12. B.O.E. n 162, of July 8, and concordant regulations.

@ 2024 Fundación Universitaria San Pablo CEU (Madrid). All rights reserved.

DSpace Software Copyright © 2002-2013 Duraspace